Our understanding of COVID-19 has evolved greatly since its first appearance in the U.S. in early 2020. Though our knowledge remains incomplete, we’ve learned a lot about the pathophysiology of the virus—especially its unique effects on the heart.
As use of cannabis products increases and evidence of possible cardiovascular harm mounts, it’s time for cardiologists to start having conversations with their patients.
Following data supporting their use for heart failure and type 2 diabetes, will sodium-glucose cotransporter 2 inhibitors find a spot in the heart failure armamentarium?
As many as 700 hearts from donors with hepatitis C are discarded each year in the U.S. New research suggests at least some of these organs may be suitable for transplant.
Even the best analytics won’t replace human interaction; protect your time with patients and colleagues. Focus on the patient-centered metrics, and try to be patient. It takes time to turn a mess into a masterpiece.
To get the operational perspective, CVB hosted a roundtable discussion with service line leaders about the opportunities and challenges they encounter around data.
Topping the list of must haves when rolling out a new complex PCI program are a solid mission to offer leading-edge technology, top-down administrative support, physician and nursing leadership, a quest for quality, and a well-oiled team.
More patients with complex diseases, added pressure to take care of them after discharge and greater expectations to demonstrate quality of care. Together, these cardiovascular service line (CVSL) realities translate into much more data to manage, and the need for someone to do it.